Recent News

• 07.17.2025 - OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
• 07.16.2025 - OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
• 06.11.2025 - OKYO Pharma to Present at the Bio International Convention
• 05.19.2025 - OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
• 05.01.2025 - FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
• 04.30.2025 - OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Recent Filings

• 07.17.2025 - EX-99.1 EX-99.1
• 07.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.16.2025 - EX-99.1 EX-99.1
• 07.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.11.2025 - EX-99.1 EX-99.1
• 06.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.27.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.19.2025 - EX-99.1 EX-99.1